To review the recent developments in our understanding of endoplasmic reticulum (ER) aminopeptidase 1 (ERAP1) function in relation to its role in major histocompatibility complex (MHC) class I peptide presentation and human leukocyte antigen (HLA) class I-associated diseases.
INTRODUCTION
Endoplasmic reticulum (ER) aminopeptidase 1 (ERAP1) is an important component of the major histocompatibility complex (MHC) class I antigen processing and presentation pathway [1] . The discovery that ERAP1 polymorphisms are associated with the MHC [human leukocyte antigen (HLA)] class I-linked diseases AS [2] , psoriasis [3] and Behçet's disease [4] , and that in each case there is evidence for gene-gene interaction (epistasis), has generated considerable interest in understanding how these variants affect the biology of HLA molecules.
Peptides derived from the cytosolic degradation of endogenous proteins are transported into the ER via peptide transporters (TAP1/TAP2). ER aminopeptidases 1 and 2 (ERAP1 and ERAP2) trim peptides to optimize their length for binding to peptidereceptive MHC class I molecules. To become peptide-receptive, MHC class I heavy chains fold and associate with b 2 -microglobulin (b 2 m). To prevent expression of suboptimally loaded or even 'empty' class I molecules, heavy chain (HC)-b 2 m complexes are retained by tapasin as part of the peptide-loading complex until they are stabilized by peptides. Following peptide binding, MHC class I complexes are transported to the cell surface where they display peptides to CD8þ T cells and NK cells. In this pathway, peptides not only represent cargo that MHC class I molecules deliver to the cell surface, but also serve as 'glue' that holds HC-b 2 m complexes together. When ER peptide supply is greatly diminished, or in the absence of b 2 m, heavy chains misfold and are degraded in the ERassociated degradation pathway [5] . In contrast, in the absence of tapasin, MHC class I complexes escape the ER, but fall apart readily on the cell surface because of the presence of suboptimal cargo.
In this issue, Ombrello et al. review the genetic evidence implicating ERAP1 single nucleotide polymorphisms (SNPs) and haplotypes in disease (Ombrello M, et al., this issue). The purpose of this review is to summarize and update what is known about the functional consequences of ERAP1 variation and loss-of-function.
ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 STRUCTURE
ERAP1 belongs to the M1 zinc aminopeptidase family, so-named for the active site zinc-binding motif [6] . ERAP1 is located in a 200 kb region on chromosome 5q15 in humans along with endoplasmic reticulum aminopeptidase 2 (ERAP2) and leucyl/ cystinylaminopeptidase (LNPEP). ERAP2 and LNPEP are also associated with AS, psoriasis and/or inflammatory bowel disease, but at this point less is known about disease-associated variants. The ERAP2 gene is absent in rodents, and in mice the product of ERAP1 was originally abbreviated as ERAAP (ER aminopeptidase associated with antigen processing). LNPEP is also known as insulin-regulated aminopeptidase (IRAP), and it is involved in endosome-mediated cross-presentation of exogenous antigen by MHC class I in dendritic cells [7] . ERAP1 has four protein domains, with domain II having catalytic activity and carrying the GAMEN and Zn-binding HExxHx18E motifs [8] (Figs. 1 and  2) . Domain I docks on top of domain II, capping off the active site and providing binding sites for the N-terminus of peptide substrates. Domain III is a small b-sandwich domain, and domain IV extends away from the active site ( Fig. 2 ). Binding of long rather than short peptides induces a conformational change with reorientation of a key catalytic residue toward the active site, providing a mechanism to explain trimming of 9-16 amino acid peptides more efficiently than 8-mers. Six AS-risk SNPs were mapped on this three-dimensional (3D) structure, revealing their location near putative substrate binding and regulatory sites (Fig. 2 ). The K528R variant, although distant from the active site, alters aminopeptidase activity against many peptide substrates [9] .
ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 FUNCTION: EFFECTS ON MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I EXPRESSION
Using traditional loss-of-function approaches, effects of reducing or eliminating ERAP1 expression on MHC class I alleles have been examined in several systems. Small inhibitory RNA (siRNA)-mediated knockdown of ERAP1 in mouse cells caused a reduction in cell surface expression of MHC class I (H-2K k and H-2D l alleles) [10] with similar effects observed for H-2K b and H-2D b in ERAP1 knockout mice [11] . MHC class I peptide loading, trafficking through the Golgi, and appearance on the cell surface were no different in ERAP1þ/-and ERAP1-/mouse cells, although ERAP1þ/þ (wild type) cells were not compared [11] . However, the stability of cell surface complexes was significantly reduced with each allele falling apart more rapidly when assembled in the absence of ERAP1. This reflects the loading of suboptimal peptides onto MHC class I when ERAP1 is lacking.
In contrast to the results in mouse cells, knocking down ERAP1 in HeLa cells increased the rate of assembly and cell surface expression of HLA class I, suggesting that when ERAP1 was present it was destroying more quality peptides than it was generating [12] . However, this result conflicts with another study [13] using HeLa cells in which ERAP1 knockdown resulted in a 10% decrease in HLA class I expression on cell surface. These differences might be because of clonal variation in HeLa cells and loss KEY POINTS ERAP1 trims peptides longer than 8-9 amino acids at their N-terminus, optimizing ligands for binding to MHC class I molecules.
Common genetic variants of ERAP1 that are associated with protection from AS confer reduced aminopeptidase activity against many substrates.
ERAP1 haplotypes encode protein allotypes that exhibit functional differences. ERAP1 allotypes found in AS are poor at restoring mouse MHC class I and HLA-BÃ27 : 05 expression in ERAP1-deficient cells, suggesting they are hypofunctional relative to allotypes found in unaffected controls.
Additional studies of naturally occurring allotypes and their effects on HLA class I alleles involved in susceptibility to AS, psoriasis and Behcet's disease are needed to better understand how these HLA molecules contribute to disease. of ERAP2 expression (K. Rock, personal communication). This is of interest because ERAP1-ERAP2 interaction may enhance biological effects on peptides not explained by a simple additive model [13, 14] . Moreover, there is a common variant in ERAP2 (rs2248374; allele frequency $50%) that causes differential mRNA splicing which results in an in-frame premature stop codon. The variant mRNA undergoes nonsense-mediated decay, and protein expression is lost [15] . The high frequency of the variant results in failure to express ERAP2 in about 25% of the population. Despite the fact that this ERAP2 variant (that is loss of expression) affects antigen presentation, MHC class I expression and would be predicted to reduce ERAP1 function, the variant is not associated with AS [16] . It is worth noting that a risk haplotype of ERAP2 that is associated with increased mRNA and protein expression is associated with the HLA-A29-associated eye disease birdshot chorioretinopathy [17] .
ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 FUNCTION: EFFECTS ON INDIVIDUAL PEPTIDES AND CROSS-PRESENTATION
ERAP1 silencing can reduce the presentation of individual peptides to epitope-specific CD8 þ T cells, consistent with the generation of many epitopes as extended peptides that require trimming in the ER for efficient MHC class I presentation [10, 11, 18] . However, the opposite has also been demonstrated, where the presence of ERAP1 reduces the supply of antigenic peptides and destroys certain epitopes that are generated more efficiently when ERAP1 is silenced [12] . The absence of ERAP1 in mice does not affect the development of CD8 þ T cells, and the immune response to influenza virus and lymphocytic choriomeningitis virus infection was not impaired, although specific epitopes were altered [19, 20] . Cross-presentation of cell-associated antigens was impaired in ERAP1 knockout mice, whereas soluble exogenous antigens were handled appropriately [19, 20] . This is in contrast to LNPEP (IRAP), which is necessary for efficient cross-presentation of exogenous antigens [7] .
ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 FUNCTION: SPECIFICITY
ERAP1 has a preference for peptide substrates of 9-16 amino acids with large hydrophobic C-terminal residues, and demonstrates slower trimming when the C-terminus is charged [21] . Peptides of 8-9 residues are spared further trimming. In contrast, ERAP2, which does not exhibit the length preference seen with ERAP1, exhibits aminopeptidase activity that is independent of C-terminal residues [21] . There is also evidence that ERAP1 prefers substrates containing hydrophobic residues (for example Leu) on the Nterminal extension, whereas ERAP2 prefers basic residues (Arg and Lys) in this region. However, factors other than the N-terminal residue also influence the efficiency of digestion. For example, in another study [13] efficient trimming of an extension containing hydrophobic and basic residues required the joint action of ERAP1 and ERAP2.
ERAP1 deficiency leads to increased recovery of N-terminally extended peptides from isolated MHC class I molecules [22] . However, a recent examination of HLA-B27-bound peptides presented in cell lines where ERAP1 was silenced revealed many Cterminally extended peptides. This article presented additional evidence that binding of C-terminally extended peptides was a consequence of the A and B pockets of HLA-B27 [23 && ], which are major determinants of its peptide binding specificity with a predilection for basic residues (Arg/Lys at P1, and Arg P2). The B pocket also confers to HLA-B27, its tendency to misfold and dimerize [24] . As ERAP1 is an aminopeptidase, the C-terminally extended peptides are unlikely to result from failed C-terminal trimming. Rather, as suggested by Chen et al., it is more likely that these peptides achieve stable binding via P2 and P1 residues and the A/B pockets of HLA-B27, and extend on their C-termini. This is of interest as it is conceivable that greater ERAP1 activity could destroy more epitopes than it creates for HLA-B27.
EFFECT OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 POLYMORPHISMS ON AMINOPEPTIDASE ACTIVITY AND EXPRESSION
There are multiple missense SNPs in ERAP1 that result in amino acid substitutions. Those with more than 5% frequency in the population are as follows: T12I, E56K,P127R, I276 M, G346D, M349 V, K528R, D575N, R725Q and Q730E, where the first letter reflects the ancestral amino acid, followed by the position in the protein, and then the nonancestral amino acid (see Table 1 in Ombrello M et al., this issue) and Fig. 1 . Genome-wide association studies (GWAS) identified risk associated with K528 and Q730, while 575N, 349 V and 725Q are protective [2, 25, 26] , with follow-up fine mapping studies identifying/confirming 127R, M349, K528, D575, R725 and Q730 as being associated with risk [26] . These studies are summarized in detail in the article by Ombrello et al. in this issue. To understand how these missense polymorphisms affect ERAP1 function, many have been generated by site-directed mutagenesis and studied in vitro and/or in cells in tissue culture. Changing K528 to 528R (K528R), R725Q and Q730E individually revealed a reduction in activity for N-terminally extended peptide precursors. However, the effect was dependent on individual peptide substrates as well as the peptide concentration [14] . In general, loss-of-function variants either have little effect on cell surface expression or cause a small reduction in canonical forms of HLA-B27, consistent with reduced editing and the studies discussed above in which ERAP1 expression led to an overall reduction in MHC class I expression [14] . ERAP1 K528R reduced its ability to produce a 9-mer peptide from a 13-mer precursor [9] , and caused a reduction in the presentation of an HLA-B27-restricted epitope to CD8þ T cells in ERAP1deficient mouse embryonic fibroblasts [23 && ].
Endoplasmic reticulum aminopeptidase 1 haplotypes and allotypes
ERAP1 variants exist as haplotypes encoding allotypes [27 && ,28] . In a study [29] of the peptides bound to HLA-B Ã 27 : 04 (peptidome) using four cell lines with different ERAP1 alleles, the presence of more loss-of-function (protective) SNPs resulted in a greater abundance of long peptides and reduced thermostability of cell surface complexes. These results are consistent with reduced optimization by protective variants. Another study of ERAP1 haplotypes from 20 individuals showed that R725Q/ Q730E and K528R/R725Q exhibited generalized reduced trimming and epitope generation from precursor peptides. However, for individual substrates, there were examples in which variants exhibited normal, hypofunctional or hyperfunctional aminopeptidase activity [28] .
A more recent study [27 && ] sequenced full-length cDNAs generated from ERAP1 mRNAs expressed in 17 AS patients and 19 controls, and then analyzed the function of the ERAP1 allotypes after re-expression in ERAP1-deficient cells. Thirteen allotypes were present in various combinations in the 36 individuals. Strikingly, there was a complete segregation of allotype combinations (pairs) found in AS patients versus controls. Allotype combinations from AS patients exhibited a reduction in generation of a specific epitope presented by the mouse class I molecule, H-2K b , and five out of six allotype pairs associated with AS were unable to restore H-2D b and H-2K b expression. In contrast, allotype pairs from controls restored MHC class I on the cell surface. When effects of ERAP1 allotypes on HLA-BÃ27 : 05 were examined, similar results were obtained, with a failure of disease-associated allotypes to increase HLA-BÃ27 : 05 expression. These data provide evidence that loss-of-function ERAP1 allotypes may confer risk, which seems inconsistent with the genetic data discussed above. Surprisingly, the 528R and 730E variants, which are protective SNPs in the GWAS studies, were over-represented in AS cases from this study. The 528R variant was present in 82.4% of allotypes (28/34 alleles from 17 patients) in AS versus 44.7% (17/38 alleles from 19 controls) of controls, with 730E present in 50% (17/34) of cases but only 34.2% (13/38) controls. Thus, the data indicating that these variants confer loss-of-function relative to other variants are consistent, whereas the genetics are inconsistent. From a genetic standpoint, this study had a very small sample size, and thus must be interpreted with caution. Similarly, studies examining functional effects of single amino acid variants must be interpreted with caution in terms of diseaserelatedness given the existence of functionally distinct allotypes.
Endoplasmic reticulum aminopeptidase 1 expression
ERAP1 haplotypes associated with AS have been shown to result in increased ERAP1 mRNA expression in monocyte-derived dendritic cells (MD-DCs) from both AS patients and healthy controls. Furthermore, ERAP1 transcript and protein levels correlated with a haplotype risk score in B-lymphoblastoid cell lines (B-LCL). Enzymatic activity of ERAP1 against fluorescent substrates was increased for AS-predisposing haplotypes in both MD-DC and B-LCL [30 & ]. To the extent that increased expression of ERAP1 would result in greater overall aminopeptidase activity in the ER, these data are consistent with increased activity being associated with risk.
EFFECT OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 ON THE IMMUNOBIOLOGY OF HUMAN LEUKOCYTE ANTIGEN-B27
HLA-B27 has a tendency to misfold and can exist on the cell surface as a disulfide-linked homodimer, or as a monomer free of b 2 m. Other MHC class I alleles can lose peptide/b 2 m and exist as monomers, whereas misfolding and dimerization are very uncommon if not unique to HLA-B27. The question of whether ERAP1 variants affect the relative amount of free heavy chain was investigated using monocytes from AS patients. Comparing C/C and C/ G at the rs27044 SNP (C encodes Q730, while G specifies 730E) with G/G revealed increased MHC class I free heavy chain with CC and CG [31] . Since the SNP encoding 730E is considered protective, this would be inconsistent with free cell surface heavy chains contributing to disease. However, this study did not identify whether HLA-B27 was contributing to the cell surface-free heavy chains. Interestingly, this study also examined the effects of ERAP1 knockdown (loss-of-function) and found increased antibody staining for unfolded (or prefolded) HLA-B27 heavy chains inside permeabilized cells, as well as increased cell surface staining with an antibody that recognizes HLA-B27 complexed with longer peptides. The effect of ERAP1 knockdown on HLA-B27 accumulation was only seen with AS-associated subtypes BÃ27 : 04 and BÃ27 : 05, and not with BÃ27 : 09 and BÃ27 : 06, which are weakly or not associated with disease, respectively [31] . No published studies have examined whether ERAP1 knockdown affects the formation of disulfide-linked HLA-B27 dimers. In our own experiments, ERAP1 knockdown mimicking loss-of-function 'protective' effects results in greater expression of HLA-B27 with long peptides (recognized by the MARB4 antibody) and greater accumulation of disulfide-linked dimers on the cell surface (submitted). This result is consistent with the increased tendency of suboptimal complexes to fall apart, which is a precursor to cell surface dimerization. If indeed loss-of-function is protective, then this result would suggest that ERAP1 effects on homodimer formation do not correlate with disease susceptibility.
In mice expressing a mouseÀhuman hybrid form of HLA-B27 or -B7 (where the peptide binding regions are fused to mouse class I a3 domains), ERAP1-deficiency reduced the expression of cell surface HLA-B27 much more than HLA-B7, consistently with there being allelic differences in the effects of ERAP1 [32 & ]. In these mice, ERAP1 loss-of-function caused either a reduction or enhancement in peptide presentation by HLA-B27 to CD8þ cytotoxic T cells (CTL) depending on the peptide studied. Interestingly, the CTL response to the HLA-B27-restricted immunodominant influenza nucleoprotein383-391 epitope is reduced when ERAP1 is absent, whereas the CTL response to the HLA-B7-restricted nucleoprotein418-426 was not affected ]. Thus, in addition to aminopeptidase activity that influences the availability of optimally sized peptides for MHC class I, ERAP1 also plays a direct role in inflammation. Whether this activity is affected by polymorphisms is not known.
CONCLUSION
ERAP1 missense SNPs that have functional significance are associated with several immune-mediated inflammatory diseases that have strong HLA class I associations, including AS, psoriasis and Behçet's disease. ERAP1 SNPs exist as haplotypes that encode functionally different proteins, or allotypes. SNPs that are associated with protection from AS confer reduced aminopeptidase activity to ERAP1 and are associated with lower expression levels, and thus can be mimicked at least in part by knocking down or eliminating expression of ERAP1. Loss of ERAP1 function reduces peptide trimming in the ER and results in the presentation of longer peptides on MHC class I molecules. For HLA-B27, the peptides can be extended either on the N-terminus or C-terminus, in contrast to other alleles that exhibit predominantly N-terminally extended epitopes. In an extensive analysis of allotypes and allotype pairs derived from HLA-B27þ individuals with AS, there was consistent evidence for reduced ERAP1 function in AS patients compared with unaffected controls, with 528R and 730E protective variants being overrepresented in AS patients. This study is provocative, but needs further genetic confirmation. Our understanding of how ERAP1 affects the biology of HLA-B51 Behçet's disease, HLA-Cw6 (psoriasis) and even HLA-B27 (AS) is incomplete. It will be essential to identify and study differences between key risk/protective haplotypes and how they affect the biology of different HLA alleles.
